Eisai remains confident ahead of "Aricept cliff"
This article was originally published in Scrip
Eisai is expecting generic competition to slash US sales of its top product Aricept (donepezil) by more than half following the first expiry of patents in this key market in November.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.